Vontobel Holding Ltd. Sells 7,677 Shares of DexCom, Inc. (NASDAQ:DXCM)

Vontobel Holding Ltd. lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,704 shares of the medical device company’s stock after selling 7,677 shares during the period. Vontobel Holding Ltd.’s holdings in DexCom were worth $8,153,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Bartlett & CO. Wealth Management LLC bought a new stake in shares of DexCom during the 4th quarter valued at $27,000. Valley National Advisers Inc. raised its position in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Harbour Investments Inc. raised its position in shares of DexCom by 55.6% during the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 120 shares during the last quarter. Atlas Capital Advisors LLC bought a new stake in shares of DexCom during the 2nd quarter valued at $33,000. Finally, MV Capital Management Inc. raised its position in shares of DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $136.52 on Wednesday. The firm has a market cap of $52.63 billion, a PE ratio of 104.21, a PEG ratio of 2.34 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a fifty day moving average price of $129.06 and a 200 day moving average price of $116.16.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business earned $0.34 EPS. The company’s revenue for the quarter was up 26.9% compared to the same quarter last year. Research analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on DXCM shares. Raymond James upped their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. Citigroup upped their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Piper Sandler upped their price objective on shares of DexCom from $135.00 to $150.00 and gave the company an “overweight” rating in a research report on Tuesday, December 19th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $141.40.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The disclosure for this sale can be found here. Insiders sold a total of 187,385 shares of company stock worth $25,256,617 in the last three months. Insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.